TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Intraoperative Narcotic Use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Post Anesthesia Care Unit (PACU) Narcotic Use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Postoperative Narcotic Use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Surgeon satisfaction with TachoSil®
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: major capillary abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum transferrin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tremor reduction (TETRAS scale, performance sub scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tremor reduction (TETRAS scale, Activity of Daily Living subscale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tremor reduction (TETRAS scale, Subject Global Impression of Change)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Achieving 75% Improvement in the Psoriasis Area and Severity Index (PASI) Scale by Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percent Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Scale at Weeks 12 and 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Device survival probability after one year
Endpoint domain: Mortality/survival
Primary endpoint: lesion detectability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Venous Plasma Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Venous Plasma Insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Venous Plasma Triglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Interstitial Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment Persistence With CT-P13
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean of All Subjects Colon Segments BBPS>=2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Grade 3 or Higher Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in functional activity in lower-limb related cortical areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in advanced motor skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Suicide Attempts
Endpoint domain: Adverse events/effects
Primary endpoint: Endoscopic healing rate of duodenal ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: digestibility of lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response rate of migraine pain-intensity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MATRICS Consensus Cognitive Battery (MCCB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UCSD Performance Based Skilled Assessment Brief Version (UPSA-B)
Endpoint domain: Life impact
Endpoint subdomain: Functional functioning
Primary endpoint: Cognitive Assessment Interview (CAI)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Primary patency detectable by duplex ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Safety/toleration of oral sildenafil
Endpoint domain: Adverse events/effects
Primary endpoint: suicide reattempt
Endpoint domain: Mortality/survival
Primary endpoint: Percentage Inhibition of the P2Y12 Receptor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Physical wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Plasma concentration of unchanged YM178
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time From Randomization to First Occurrence of Composite of All Symptomatic Venous Thromboembolism (VTE) and VTE Related Death
Endpoint domain: Mortality/survival
Primary endpoint: Event Rate Based on Time From Randomization to the First Occurrence of Major Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants without adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Skeletal Muscle Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Peak serum GH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Local recurrence rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Airway Volume (iVaw)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Airway Resistance (iRaw)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Low Attenuation or Emphysema Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of patients with fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Quality of Visualization of CECT Images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients Categorized with Hypersomnolence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Description and documentation of acne lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in P1NP response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Wound dehiscence
Endpoint domain: Adverse events/effects
Primary endpoint: Pain (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Time in Range: Sensor Glucose Values Between 70-180 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Time in Range: Sensor Glucose Readings <70 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: X-ray measurements of talus-calcaneus angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: X-ray measurements of talus-navicular angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: X-ray measurements of talus-first metatarsal angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: HRV dynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients choosing Combination therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neurotrophic Factor BDNF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection accuracy change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Willingness to Participate (WTP) Mean Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of low risk patients who get a PSA test
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change From Baseline Hair Growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative abundance of faecal bifidobacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: IBS symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Different Substitution Solutions Administered
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Area Under the Concentration-time Curve (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of medication discrepancies
Endpoint domain: Adverse events/effects
Primary endpoint: Percent change in bone mineral density (BMD) at lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Grade of intraepithelial neoplasia prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Treatment Action, adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: upper airway temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: upper airway humidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of concussions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Subjects with >15% Decrease in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Vaginal Mucus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slow pathway modification/elimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor recovery prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Pressure Pain Thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vibration Thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Six-minute Walking Test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Pain Scale (VAS)
Endpoint domain: Adverse events/effects
Primary endpoint: Perceived Quality of Life Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Anxiety Severity and Impairment Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Subjects With HPA Axis Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum tolerated dose of bendamustine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes From Baseline in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes From Baseline in Percent Predicted Forced Vital Capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: changes in brain lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Difference in Total Distance During 6-Minute Walk from Baseline to Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Difference in Total Distance During 6-Minute Walk from Post Treatment to Week 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of ICAR19 CAR-T cells
Endpoint domain: Adverse events/effects
Primary endpoint: PAP Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 3 or more doses of IPTp
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of 1-Hydroxymidazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Predicted Function of FEV1 at Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage Change From Baseline in Percent-Predicted of FEV1 at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maintain cytogenetic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety and tolerability of ranibizumab
Endpoint domain: Adverse events/effects
Primary endpoint: Objective clinical tumor regression response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Slit-lamp Findings > Grade 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Responses to Comfort Related Symptoms/Complaints
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Contact Lens Deposits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Swanson, Nolan and Pelham Teacher and Parent Rating Scale (SNAP-IV)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adult ADHD Self-Report Scale-V1.1 (ASRS-V1.1)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Conners' Continuous Performance Test (CPT-III)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of medication delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety of medication delivery
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Concentration Time Curve (AUC) From Time Zero to 21 Days [AUC(0-21d)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC Time Zero Extrapolated to Infinity [AUC(INF)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective experiences of respiratory distress associated with exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Traumatic stress symptom severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CI electrode's scalar position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interictal Discharge frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MMSE (Mini-Mental State Examination)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Caregiver perceptions of overall helpfulness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of participants viewing e-PRO online report
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of Hypertension (HTN) in Diabetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of herpetic episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numbers of patients experiencing toxicities/adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Concordance in signal between standard needles and EEG electrode patch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: titers of COVID-19 neutralising antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Abdominal pain frequency and severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in fractional representation of myeloid-derived suppressor cells (MDSC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Functional status change of myeloid-derived suppressor cells (MDSC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Presence of tortuosity of conjunctival vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absorption of TMC435
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C Reactive Protein (Area Under the Curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All major congenital malformations (MCMs) combined
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Completed low dose CT scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in creatine kinase (CK)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inpatient colectomy rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of days for complete reepithelialization of the burn wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychological characterization
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: First COPD Exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: reductions in sexual risk behaviors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Breast milk production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sustained clinical cure of CDI at day 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quadriceps strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Medication and treatment prescribed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: International Physical Activity Questionnaire - Short Form results
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Biodex Balance System (BBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Cerebral Palsy
Endpoint domain: Mortality/survival
Primary endpoint: Blood levels of topotecan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: VAS ratings of mood and anxiety/stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cleveland Clinic Constipation Score (CCCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fecal Incontinence Severity Index (FISI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: percentage of weight loss at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percentage of change in BMI at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Percentage of participants using controller medications for asthma
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Tremor Rating Scale (TRS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change From Baseline in ACM-I Questionnaire Total Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Physical Function ICU Test-scored
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Leak airway pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Headache Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with abnormal laboratory values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Relative risk for postoperative pulmonary incidents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of biopsy-proven-acute-rejection and treatment failure
Endpoint domain: Mortality/survival
Primary endpoint: Mean Change in Right Ventricular Ejection Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in SF-36 questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Foot and Ankle Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Overall Clinical Benefit Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biometrical Adherence to Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to Therapy According to Physician Approximation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Response at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in neural function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Visual Analog Scale Outcome-1
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Visual Analog Scale Outcome-2
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Visual Analog Scale Outcome-3
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Change in percentage ventilated lung volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: % of Red Blood Cells With Hemolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Dual Label 24 Hour In Vivo % Recovery of Red Blood Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes